124 related articles for article (PubMed ID: 10497180)
1. Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions.
Strumberg D; Nitiss JL; Dong J; Kohn KW; Pommier Y
J Biol Chem; 1999 Oct; 274(40):28246-55. PubMed ID: 10497180
[TBL] [Abstract][Full Text] [Related]
2. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
Hsiung Y; Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1995 Sep; 270(35):20359-64. PubMed ID: 7657608
[TBL] [Abstract][Full Text] [Related]
3. Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions.
Strumberg D; Nitiss JL; Rose A; Nicklaus MC; Pommier Y
J Biol Chem; 1999 Mar; 274(11):7292-301. PubMed ID: 10066792
[TBL] [Abstract][Full Text] [Related]
4. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
Jannatipour M; Liu YX; Nitiss JL
J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
[TBL] [Abstract][Full Text] [Related]
5. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
Wasserman RA; Wang JC
Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
[TBL] [Abstract][Full Text] [Related]
6. Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
Strumberg D; Nitiss JL; Dong J; Walker J; Nicklaus MC; Kohn KW; Heddle JG; Maxwell A; Seeber S; Pommier Y
Antimicrob Agents Chemother; 2002 Sep; 46(9):2735-46. PubMed ID: 12183223
[TBL] [Abstract][Full Text] [Related]
7. Position-specific trapping of topoisomerase II by benzo[a]pyrene diol epoxide adducts: implications for interactions with intercalating anticancer agents.
Khan QA; Kohlhagen G; Marshall R; Austin CA; Kalena GP; Kroth H; Sayer JM; Jerina DM; Pommier Y
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12498-503. PubMed ID: 14523238
[TBL] [Abstract][Full Text] [Related]
8. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
9. Atp-bound topoisomerase ii as a target for antitumor drugs.
Wang H; Mao Y; Zhou N; Hu T; Hsieh TS; Liu LF
J Biol Chem; 2001 May; 276(19):15990-5. PubMed ID: 11278845
[TBL] [Abstract][Full Text] [Related]
10. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
11. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
[TBL] [Abstract][Full Text] [Related]
12. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
13. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
14. Differential in vitro interactions of a series of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase IIalpha and IIbeta isoforms.
van Hille B; Perrin D; Hill BT
Anticancer Drugs; 1999 Jul; 10(6):551-60. PubMed ID: 10885903
[TBL] [Abstract][Full Text] [Related]
15. Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase.
Lynn R; Giaever G; Swanberg SL; Wang JC
Science; 1986 Aug; 233(4764):647-9. PubMed ID: 3014661
[TBL] [Abstract][Full Text] [Related]
16. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
18. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
19. A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells.
Walker JV; Nitiss KC; Jensen LH; Mayne C; Hu T; Jensen PB; Sehested M; Hsieh T; Nitiss JL
J Biol Chem; 2004 Jun; 279(25):25947-54. PubMed ID: 15037624
[TBL] [Abstract][Full Text] [Related]
20. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast.
Meczes EL; Marsh KL; Fisher LM; Rogers MP; Austin CA
Cancer Chemother Pharmacol; 1997; 39(4):367-75. PubMed ID: 9025779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
